Sela-Paswell et al. previously demonstrated that neutralizing antibodies to host gelatinase B could be highly effective in alleviating colitis in murine models (81), with a humanized version of this antibody having recently undergone phase I clinical trials (ClinicalTrials.gov identifier: NCT01831427). This evidence concerns the gene MMP9 and colitis.